About Hepion Pharmaceuticals
Hepion Pharmaceuticals is a company based in Edison (United States) founded in 2013.. Hepion Pharmaceuticals has completed 1 acquisition, including Ciclofilin Pharmaceuticals. Hepion Pharmaceuticals offers products and services including Rencofilstat and AI-POWR. Hepion Pharmaceuticals operates in a competitive market with competitors including Replimune, Candel Therapeutics, MiNA Therapeutics, SillaJen and Adlai Nortye, among others.
- Headquarter Edison, United States
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Hepion Pharmaceuticals, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-13.19 M73.04as on Dec 31, 2024
-
EBITDA
$-19.32 M57.26as on Dec 31, 2024
-
Latest Funding Round
$5 M (USD), Post-IPO
Oct 03, 2023
-
Investors
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Hepion Pharmaceuticals
Hepion Pharmaceuticals is a publicly listed company on the OTC with ticker symbol HEPA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Hepion Pharmaceuticals
Hepion Pharmaceuticals offers a comprehensive portfolio of products and services, including Rencofilstat and AI-POWR. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhibitor targeting cyclophilins for treating liver fibrosis and NASH
AI system for decoding diseases and developing targeted therapies
Unlock access to complete
Unlock access to complete
Funding Insights of Hepion Pharmaceuticals
- Total Funding Total Funding
- Total Rounds 6
- Last Round Post-IPO — $5.0M
-
First Round
First Round
(14 Feb 2014)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2023 | Amount | Post-IPO - Hepion Pharmaceuticals | Valuation |
investors |
|
| Mar, 2019 | Amount | Post-IPO - Hepion Pharmaceuticals | Valuation |
investors |
|
| Mar, 2019 | Amount | Debt – Conventional - Hepion Pharmaceuticals | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Hepion Pharmaceuticals
Hepion Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Ciclofilin Pharmaceuticals. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
US-based, preclinical stage biotech developing cyclophilin-inhibitors for infectious, inflammatory, and degenerative diseases. Acquired by ContraVir
|
2014 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Hepion Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Hepion Pharmaceuticals Comparisons
Competitors of Hepion Pharmaceuticals
Hepion Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Replimune, Candel Therapeutics, MiNA Therapeutics, SillaJen and Adlai Nortye, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of oncolytic immunotherapies
|
|
| domain | founded_year | HQ Location |
Viral immunotherapies are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Small activating RNA therapeutics are developed to restore gene function.
|
|
| domain | founded_year | HQ Location |
Oncolytic immunotherapeutics are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Immune oncolytic therapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for fibrosis, cirrhosis, and liver cancer are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Hepion Pharmaceuticals
Frequently Asked Questions about Hepion Pharmaceuticals
When was Hepion Pharmaceuticals founded?
Hepion Pharmaceuticals was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Where is Hepion Pharmaceuticals located?
Hepion Pharmaceuticals is headquartered in Edison, United States. It is registered at Edison, New Jersey, United States.
What does Hepion Pharmaceuticals do?
Hepion Pharmaceuticals provides therapeutics for chronic liver disorder. The company offers pleiotropic drug-based therapy for the treatment of fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis (NASH), viral hepatitis, and other liver diseases. The leading candidate of the company CRV431 is in phase 1 of clinical trial and targets multiple biochemical pathways.
Who are the top competitors of Hepion Pharmaceuticals?
Hepion Pharmaceuticals's top competitors include Replimune, MiNA Therapeutics and Alentis Therapeutics.
What products or services does Hepion Pharmaceuticals offer?
Hepion Pharmaceuticals offers Rencofilstat and AI-POWR.
Is Hepion Pharmaceuticals publicly traded?
Yes, Hepion Pharmaceuticals is publicly traded on OTC under the ticker symbol HEPA.
How many acquisitions has Hepion Pharmaceuticals made?
Hepion Pharmaceuticals has made 1 acquisition, including Ciclofilin Pharmaceuticals.
What is Hepion Pharmaceuticals's ticker symbol?
The ticker symbol of Hepion Pharmaceuticals is HEPA on OTC.